Study on Mpox vaccination strategies in Sweden highlights the need for booster doses
Published: 2026-01-08
Our latest data highlights ‘Latest study on Mpox vaccination highlights the need for booster doses’ focuses on the work by Espinosa-Gongora et al. (2025). The researchers aimed to better understand immune responses to the intradermal Modified Vaccinia Ankara–Bavarian Nordic (MVA-BN) vaccine administered to an at risk group in Sweden during the global Mpox outbreak in 2022-2023. The study found that neutralising antibodies specific to mpox virus decline significantly within 3 to 9 months after vaccination, though levels often remain above pre‑vaccination baselines. Serum samples were tested using microneutralisation assays with live virus on Vero cells, and antibody titers were statistically compared across timepoints using mixed‑effects regression and paired tests. These findings have important implications for vaccine policy, and highlight the potential need for booster doses to sustain immunity in populations at ongoing risk.
To find out more about the study, please read the data highlight.
If you are interested in having your work turned into a data highlight, please contact the portal team.